Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

INTRODUCTION: Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based on observational data from t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Risk Manag Healthc Policy
Hlavní autoři: Canonica, Giorgio Walter, Colombo, Giorgio Lorenzo, Rogliani, Paola, Santus, Pierachille, Pitotti, Claudia, Di Matteo, Sergio, Martinotti, Chiara, Bruno, Giacomo Matteo
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6986414/
https://ncbi.nlm.nih.gov/pubmed/32158289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RMHP.S211321
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky